Outlook Therapeutics (OTLK) Current Leases (2015 - 2026)
Outlook Therapeutics (OTLK) reported Current Leases of $62003.0 for Q1 2026, up 13.92% year-over-year from $54425.0 in Q1 2025, and up 1.44% quarter-over-quarter from $61125.0 in Q4 2025.
Outlook Therapeutics (OTLK) Current Leases (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Current Leases data on file, last reported at $62003.0 in Q1 2026.
- Current Leases for Q1 2026 came in at $62003.0, up 13.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $62003.0 (up 13.92% YoY), and the FY2025 annual result was $58897.0, up 15.7% from the prior year.
- Current Leases improved to $62003.0 in Q1 2026 per OTLK's latest filing, from $61125.0 in the prior quarter.
- Over five years, Current Leases peaked at $62003.0 in Q1 2026 and troughed at $1084.0 in Q4 2023.
- A 5-year average of $35868.8 and a median of $41687.0 in 2022 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases tumbled 91.07% in 2023, then surged 4756.55% in 2024.
- A 5-year view of Current Leases shows it stood at $12137.0 in 2022, then plunged by 91.07% to $1084.0 in 2023, then surged by 4756.55% to $52645.0 in 2024, then gained by 16.11% to $61125.0 in 2025, then increased by 1.44% to $62003.0 in 2026.
- Business Quant data shows OTLK's Current Leases at $62003.0 in Q1 2026, $61125.0 in Q4 2025, and $58897.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | 62,003.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,003.00 |
| Dec 31, 2025 | 61,125.00 |
| Sep 30, 2025 | 58,897.00 |
| Jun 30, 2025 | 56,560.00 |
| Mar 31, 2025 | 54,425.00 |
| Dec 31, 2024 | 52,645.00 |
| Sep 30, 2024 | 50,907.00 |
| Jun 30, 2024 | 31,801.00 |
| Dec 31, 2023 | 1,084.00 |
| Sep 30, 2023 | 4,267.00 |
| Jun 30, 2023 | 7,349.00 |
| Mar 31, 2023 | 10,332.00 |
| Dec 31, 2022 | 12,137.00 |
| Sep 30, 2022 | 26,995.00 |
| Jun 30, 2022 | 38,203.00 |
| Mar 31, 2022 | 45,171.00 |
| Dec 31, 2021 | 22,460.00 |
| Sep 30, 2021 | 42,854.00 |
| Jun 30, 2021 | 27,459.00 |
| Mar 31, 2021 | 26,972.00 |